Compare Core Scientific Inc (CORZ) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs UiPath Inc — how do they compare? Core Scientific Inc trades at $19.66 (market cap $6.25B), while UiPath Inc trades at $15.53 (market cap $8.08B). The key difference: UiPath Inc is the larger of the two by market cap, and UiPath Inc is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals.
| CORZ | PATH | |
|---|---|---|
Market Cap | $6.25B | $8.08B |
Sector | Technology | Technology |
52-Week High | $29.16 | $19.29 |
52-Week Low | $13.55 | $9.38 |
Enterprise Value | $8.78B | $6.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.
While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.
UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.
PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
